ANTX
AN2 Therapeutics Inc
4.90$
-0.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.8% | -12.6% | -10.5% | -9.9% | -5.7% | -11.7% | -6.8% | -11.3% | -7.9% | +41.2% | -6.6% | |
| – | -12.6% | +5.3% | -7.6% | -9.1% | -11.7% | -19.4% | -2.9% | -5.2% | -6.4% | +46.0% | -8.6% | |
| – | -52.0% | +57.8% | +8.4% | +25.2% | -36.3% | -6.4% | -8.8% | -1.2% | +10.8% | +168.2% | -17.1% | |
| – | -13.3% | +6.4% | -8.5% | -10.6% | -10.5% | -19.8% | -6.2% | -1.6% | -6.3% | +47.0% | -8.1% | |
| – | – | -64.3% | -40.0% | +233.3% | -70.0% | +0.0% | +800.0% | -85.2% | +125.0% | -66.7% | +0.0% | |
| – | -5.4% | -24.1% | -5.0% | -1.1% | +2.2% | -21.7% | -12.9% | -1.8% | +29.6% | -35.5% | +0.4% | |
| – | -5.4% | -24.1% | -5.0% | -1.1% | +2.2% | -21.7% | -73.6% | +224.6% | +27.2% | -36.2% | +0.4% | |
| – | -45.1% | -9.1% | -22.5% | -9.2% | +93.9% | -7.4% | -31.2% | +5.3% | +35.7% | -13.4% | -24.8% | |
| – | -10.3% | -11.3% | -11.1% | -10.9% | -6.6% | -10.4% | -6.1% | -12.3% | -12.1% | +54.1% | -7.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +15.9% | +0.1% | +0.2% | +0.1% | +0.1% | +0.6% | +0.4% | +0.3% | -0.2% | +12.7% | +31.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.